Healthcare funds see performance divergence

healthcare Platinum ETFs BetaShares CFS

20 November 2020
| By Laura Dew |
image
image
expand image

While healthcare has been one of the stand-out sectors since the start of the year, it has been important for investors to consider fund selection as there has been divergent performance between the individual funds.

Earlier this month, healthcare was named as the sector most likely to outperform in 2021 with 73% expecting stocks in that sectors to increase in value.

Using FE Analytics, there were four healthcare funds in the Australian Core Strategies universe; ETFS S&P Biotech, Platinum International Health Care, CFS Wholesale Global Health and Biotechnology and BetaShares Global Healthcare ETF Currency Hedged.

ETFS S&P Biotech returned 31.6% over one year to 30 October, 2020, while Platinum International Health Care returned 24.9%.

The ETFS fund aimed to provide investors with exposure to US biotechnology companies which were engaged in research and development of products based on genetic analysis and genetic engineering. With 124 equally-weighted holdings, ETFS said this reduced single-stock risk especially as biotechnology was a risky sector.

However, there were fewer returns for CFS Wholesale Global Health and Biotechnology and BetaShares Global Healthcare ETF Currency Hedged which had returned 10.1% and 2.3%.

The difference was even more pronounced since the start of the year with the ETFS and Platinum funds seeing double-digit returns while the BetaShares fund reported losses of 4.5%. The CFS fund saw returns since the start of the year of 2.8%. 

Read more about:

AUTHOR

Recommended for you

sub-bgsidebar subscription

Never miss the latest news and developments in wealth management industry

MARKET INSIGHTS

Completely agree Peter. The definition of 'significant change is circumstances relevant to the scope of the advice' is s...

1 month 3 weeks ago

This verdict highlights something deeply wrong and rotten at the heart of the FSCP. We are witnessing a heavy-handed, op...

1 month 4 weeks ago

Interesting. Would be good to know the details of the StrategyOne deal....

2 months ago

SuperRatings has shared the median estimated return for balanced superannuation funds for the calendar year 2024, finding the year achieved “strong and consistent positiv...

2 weeks 2 days ago

Original bidder Bain Capital, which saw its first offer rejected in December, has returned with a revised bid for Insignia Financial....

1 week 2 days ago

The FAAA has secured CSLR-related documents under the FOI process, after an extended four-month wait, which show little analysis was done on how the scheme’s cost would a...

6 days 23 hours ago

TOP PERFORMING FUNDS